

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection
Hyris CE-IVD marked test for COVID human diagnostic "bKIT Virus Finder COVID-19" is at the core of the signature Article "Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection", from the Department of Laboratory Medicine of the National Institute for The Study and Treatment of Cancer IRCCS "Fondazione G Pascale" (IRCCS Pascale), of Naples (Italy)
The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. Up to now, laboratory real-time PCR is the standard of care, but requires a fully equipped laboratory and significant infrastructure. Consequently, new diagnostic tools are required.
Professor Leonardo Miscio and his colleagues evaluated the diagnostic accuracy of Hyris point-of-care rapid test "bKIT Virus Finder COVID-19", both by a retrospective and a prospective analysis.
Results obtained are entirely comparable to the standard laboratory-based real-time PCR methods for all the analyzed samples, with a much faster result and no need for an equipped facility.
This authoritative Article furtherly strengthens the Hyris System's relevance for human diagnostic, now empowered via the CE-IVD marked 'bKIT Virus Finder COVID-19', as it represents indeed a promising tool to improve the health surveillance and to increase the overall capacity of SARS-CoV-2 testing.
Hyris System confirms to be a key asset in the global fight against the last Coronavirus.
Read the full article HERE
-
Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson
-
Hyris and Singlabs signed a distributorship agreement for Singapore
-
Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.
-
Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine
-
Hyris to participate in SEI 2022 in Leon, hosted by the Sociedad Española de Immunologia
-
Hyris' new T-cell Test is finally available to EU Countries to easily map patients' cellular immunity to SARS-CoV-2
-
Hyris presented Hyris System, its distruptive signature technology, at Analytica 2022 in Munich
-
A new T-cell activation assay based on Hyris technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity.
-
Hyris and its network want to make pragmatic impact Helping Ukrainian Families
-
Hyris presented its new, disruptive T-Cell test at the international conference "A-Wish", fully embracing the Immunology sector to better fight COVID-19 and beyond.